Tau Protein News and Research

RSS

Tau proteins are microtubule-associated proteins found in neurons in the brain.

Immunotherapy reverses memory problems in animal model of Alzheimer's disease

A new study from the University of Texas Medical Branch at Galveston has revealed that a single dose of an immunotherapy reverses memory problems in an animal model of Alzheimer's disease. The article appears in the March 25 issue of the Journal of Neuroscience.

26 Mar 2015

UCLA-led team validates first standardized protocol for tracking early signs of Alzheimer's disease

After six years of painstaking research, a UCLA-led team has validated the first standardized protocol for measuring one of the earliest signs of Alzheimer's disease -- the atrophy of the part of the brain known as the hippocampus.

26 Mar 2015

Study: Progression of dysfunctional tau protein drives cognitive decline in Alzheimer's disease

By examining more than 3,600 postmortem brains, researchers at Mayo Clinic's campuses in Jacksonville, Florida, and Rochester, Minnesota, have found that the progression of dysfunctional tau protein drives the cognitive decline and memory loss seen in Alzheimer's disease.

24 Mar 2015

AbbVie signs exclusive worldwide license agreement with C2N for Alzheimer's disease therapies

AbbVie today announced that it has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders.

19 Mar 2015

Intrinsically disordered proteins have ability to alter their configuration

Like the shape-shifting robots of "Transformers" fame, a unique class of proteins in the human body also has the ability to alter their configuration. These so-named intrinsically disordered proteins (IDPs) lack a fixed or ordered three-dimensional structure, which can be influenced by exposure to various chemicals and cellular modifications.

26 Feb 2015

New skin test may help detect abnormal proteins in patients with Alzheimer's and Parkinson's diseases

Scientists have discovered a skin test that may shed new light on Alzheimer's and Parkinson's diseases, according to a study released today will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, D.C., April 18 to 25, 2015.

25 Feb 2015

Scientists identify role of tau-associated MAPT gene in development of Alzheimer's disease

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, has identified the microtubule-associated protein tau (MAPT) gene as increasing the risk for developing Alzheimer's disease (AD).

18 Feb 2015

UAB research suggests potential therapeutic target for patients with frontotemporal dementia

Drugs that boost the function of a specific type of neurotransmitter receptor may provide benefit to patients with the second most common type of dementia, according to research by scientists at the University of Alabama at Birmingham published today in the Journal of Neuroscience.

4 Dec 2014

Blocking key brain receptor cell could neutralize biological consequences of Alzheimer's

Blocking a key receptor in brain cells that is used by oxygen free radicals could play a major role in neutralizing the biological consequences of Alzheimer's disease, according to researchers at Temple University.

19 Nov 2014

Multi-institutional study establishes new criteria for Alzheimer's-related memory disorder

A multi-institutional study has defined and established criteria for a new neurological disease closely resembling Alzheimer's disease called primary age-related tauopathy (PART).

14 Nov 2014

Study defines, establishes criteria for primary age-related tauopathy

A multi-institutional study has defined and established criteria for a new neurological disease closely resembling Alzheimer's disease called primary age-related tauopathy (PART). Patients with PART develop cognitive impairment that can be indistinguishable from Alzheimer's disease, but they lack amyloid plaques. Awareness of this neurological disease will help doctors diagnose and develop more effective treatments for patients with different types of memory impairment.

13 Nov 2014

New culture system confirms amyloid theory, can revolutionize drug discovery for Alzheimer's disease

An innovative laboratory culture system has succeeded, for the first time, in reproducing the full course of events underlying the development of Alzheimer's disease.

13 Oct 2014

TauRx achieves target enrolment in second LMTX Phase III clinical trial for Alzheimer's disease

TauRx Therapeutics Ltd has achieved its target enrolment of 700 subjects with mild Alzheimer's disease into the second of its two Phase III clinical trials of LMTX, a tau aggregation inhibitor, for the treatment of Alzheimer's disease.

22 Sep 2014

Study shows bryostatin plays key role in slowing or reversing Alzheimer's disease

Neurotrope, Inc. (OTCQB: NTRP) today announced that results from a new study, entitled, "PKCe Deficits in Alzheimer's Disease Brains and Skin Fibroblasts," published in the recent edition of the peer-reviewed Journal of Alzheimer's Disease and co-authored by Tapan K. Khan, Ph.D.; Abhik Sen, Ph.D.; Jarin Hongpaisan, Ph.D.; Chol S. Lim, Ph.D.; Thomas J. Nelson, Ph.D., and; Dr. Daniel L. Alkon, each of the Blanchette Rockefeller Neurosciences Institute (BRNI), provide further indication of the role that protein kinase C epsilon (PKCe) may play in the potential treatment of Alzheimer's disease (AD).

19 Aug 2014

Reducing brain levels of tau protein effectively blocks development of childhood epilepsy

Researchers at the Gladstone Institutes have shown that reducing brain levels of the protein tau effectively blocks the development of disease in a mouse model of Dravet syndrome, a severe intractable form of childhood epilepsy.

14 Aug 2014

PLXNA4 gene may increase risk of developing Alzheimer's disease

Researchers from Boston University School of Medicine report variants in a new gene, PLXNA4, which may increase the risk of developing Alzheimer's disease (AD). The discovery of this novel genetic association may lead to new drug treatment options that target PLXNA4 specifically.

28 Jul 2014

BrightFocus offers grants to 55 scientists for Alzheimer's disease and vision research

BrightFocus Foundation, a nonprofit organization funding cutting-edge, innovative research on Alzheimer's disease and the vision diseases of glaucoma and macular degeneration, today announced the recipients of new research grant awards, offered to 55 scientists in 19 U.S. states, the District of Columbia, and five foreign countries.

11 Jul 2014

Suppressing hyperactivity of calcium channels alleviates familial Alzheimer's disease

In 2008, researchers at the Perelman School of Medicine at the University of Pennsylvania showed that mutations in two proteins associated with familial Alzheimer's disease (FAD) disrupt the flow of calcium ions within neurons.

15 May 2014

Bristol-Myers Squibb completes acquisition of iPierian

Bristol-Myers Squibb Company and iPierian, Inc. announced today that Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain.

29 Apr 2014

NeuroPhage engineers series of molecules with potential to treat most neurodegenerative diseases

Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases.

23 Apr 2014